Scarica l'app Stockscreener
50.18
1.41%
0.70
Dopo l'orario di chiusura:
50.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$49.48
Aprire:
$51.26
Volume 24 ore:
1.54M
Relative Volume:
0.75
Capitalizzazione di mercato:
$8.42B
Reddito:
$1.56B
Utile/perdita netta:
$152.72M
Rapporto P/E:
55.79
EPS:
0.8994
Flusso di cassa netto:
$221.80M
1 W Prestazione:
-0.20%
1M Prestazione:
-4.82%
6M Prestazione:
+56.81%
1 anno Prestazione:
+73.93%
Intervallo 1D:
$50.08
$51.29
Intervallo di 1 settimana:
$48.62
$51.66
Portata 52W:
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
50.18 | 8.30B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
18.34 | 57.64B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.47 | 42.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.68 | 30.56B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
529.14 | 22.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-29 | Downgrade | BofA Securities | Neutral → Underperform |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: A Look At The 14.15% Potential Upside - DirectorsTalk Interviews
S&CO Inc. Takes Position in Alkermes plc $ALKS - MarketBeat
Alkermes PLC (ALKS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes plc $ALKS Stock Position Trimmed by Empowered Funds LLC - MarketBeat
Quantinno Capital Management LP Grows Holdings in Alkermes plc $ALKS - MarketBeat
Bank of America Corp DE Trims Position in Alkermes plc $ALKS - MarketBeat
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - TradingView
Alkermes Lowers Interest Rate Spreads with Amendment to Credit Agreement - Kalkine Media
Alkermes amends credit agreement to reduce interest rates on term loans - Investing.com Nigeria
Form 8K Alkermes plc. For: 12 August By Investing.com - Investing.com Canada
Alkermes Reduces Spreads on $1.52 Billion Term Loans by Up to 75 bps - TradingView
Alkermes (NASDAQ: ALKS) lowers interest spreads on large term loan A and B debt - Stock Titan
Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities - marketscreener.com
Hennion & Walsh Asset Management Inc. Makes New Investment in Alkermes plc $ALKS - MarketBeat
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance
Alkermes plc (ALKS) Stock Analysis: Evaluating a 13.89% Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.st
The Manufacturers Life Insurance Company Sells 42,319 Shares of Alkermes plc $ALKS - MarketBeat
Royal Bank of Canada Sells 21,159 Shares of Alkermes plc $ALKS - MarketBeat
(ALKS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amundi Increases Stake in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Acquired by California State Teachers Retirement System - MarketBeat
Sei Investments Co. Has $5.44 Million Stake in Alkermes plc $ALKS - MarketBeat
Major Decision: Nancy Snyderman Exercises Options, Realizing $116K At Alkermes - Benzinga
Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing - marketscreener.com
Form 4 Alkermes plc. For: 3 August By Investing.com - Investing.com South Africa
Alkermes Plc (ALKS) Stock Analysis: A Compelling 14% Upside Potential For Investors - DirectorsTalk Interviews
Research Analysts Set Expectations for Alkermes Q3 Earnings - MarketBeat
Seven Fleet Capital Management LP Acquires New Shares in Alkermes plc $ALKS - MarketBeat
Why Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing - simplywall.st
Alkermes plc 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-07-31 - Seeking Alpha
H.C. Wainwright reiterates Neutral stock rating on Alkermes - Investing.com
Stempoint Capital LP Acquires Shares of 80,492 Alkermes plc $ALKS - MarketBeat
Alkermes Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says - marketscreener.com
Entropy Technologies LP Sells 40,839 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down - The Globe and Mail
ALKS: Strong Q2 revenue, robust orexin pipeline progress, and LUMRYZ integration drive growth - TradingView
Piper Sandler raises Alkermes stock price target on pipeline value - Investing.com
Alkermes Q2 Earnings Call Highlights - Yahoo Finance
Alkermes Q2 2026 slides: revenue surges 27% but acquisition costs squeeze - Investing.com
Earnings call transcript: Alkermes tops Q2 2026 estimates but shares fall premarket - Investing.com
Alkermes plc Revenue Breakdown – NASDAQ:ALKS - TradingView
ALKS Looks 64.8% Overvalued on GF Value™ - GuruFocus
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
3.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):